Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1700a ↗At a glance
Journal article in The Medical Letter on Drugs and Therapeutics, 2024. Major MEDLINE topics: Dermatitis, Seborrheic, Dermatologic Agents. Cited 2 times so far (Crossref).
Abstract (original language)
The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Cite
APA
(2024). Roflumilast Foam (Zoryve) for Seborrheic Dermatitis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1700a
Vancouver
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1700a
BibTeX
@article{euvimed2024,
title = {Roflumilast Foam (Zoryve) for Seborrheic Dermatitis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1700a}
}
EUVIMED